Purdue Pharma Settlement Shuts Out 80,000 Opioid Victims: 'A Punch in the Gut'

Mary Jannotta spent decades working deli counters at Philadelphia-area supermarkets before a botched back surgery in 2008 left her in chronic pain. Her doctor prescribed OxyContin repeatedly—Purdue Pharma's blockbuster opioid that the company later admitted it had criminally marketed. When her prescriptions stopped, she found herself in Kensington, Philadelphia's open-air drug market, searching for pills. She lost her car, her home, and eventually her grandson Tyler, who died of an overdose at 24 after first stealing her prescription pills as a teenager.

When Purdue filed for bankruptcy in 2019, Jannotta joined nearly 140,000 other victims in filing claims against the company. After years of waiting through litigation, Supreme Court challenges, and bankruptcy negotiations, a federal judge approved a new $7.4 billion settlement plan in November 2025. But that plan will shut out tens of thousands of victims who originally sought justice, according to a joint investigation by ProPublica and The Philadelphia Inquirer.

Fewer than half of those who filed claims against Purdue will receive any compensation under the new plan—despite company statements touting it as "the only opioid settlement to date that meaningfully compensates individual victims."

The Winnowing of Victims

Court records reveal a settlement that grew more restrictive with each revision. The original plan, rejected by the Supreme Court in 2024 because it improperly shielded the Sackler family from future lawsuits, included provisions that were eliminated or weakened in subsequent negotiations conducted largely outside public view.

The most significant change involved documentation requirements. The initial settlement allowed victims to submit sworn affidavits—legally binding statements made under oath—in lieu of medical records or prescriptions to prove they had used Purdue opioids. This provision recognized a practical reality: Purdue sold OxyContin for decades, and medical record retention laws vary by state, with most requiring doctors, hospitals, and pharmacies to keep records for only a few years.

The new plan eliminated the affidavit option. Victims must now produce physical documentation—prescriptions, medical records, or legal evidence—from years or decades past. For many, such records no longer exist.

"I can't turn up prescriptions for my son back when he was young, years ago," said Ellen Isaacs, a Michigan resident whose son Ryan died from an overdose at 33 in 2018. "They're not available anymore." Ryan's addiction, she said, began when he was prescribed OxyContin after a high school injury.

Similar sworn statement provisions have been permitted in other major bankruptcy cases involving historical harm—such as sexual abuse claims against the Boy Scouts and the Catholic Church—precisely because physical evidence from years past is often impossible to obtain. The removal of this option from the Purdue settlement represents a significant departure from precedent.

Shrinking Compensation

Even victims who successfully navigate the documentation maze face dramatically reduced payments. Estimated settlement amounts for family members who lost loved ones to fatal overdoses have dropped to as little as $8,000—down from $48,000 under the previous plan. The new agreement also eliminated compensation entirely for teenagers who purchased Purdue drugs on the street, a population that was eligible under earlier versions.

The $7.4 billion settlement includes $870 million specifically earmarked for individual victims. But with fewer than 60,000 of the original 140,000 claimants expected to qualify, the per-person amounts remain a fraction of what was initially anticipated.

The math is stark: more than 300,000 Americans have died from prescription opioid overdoses since the crisis began, and millions more became addicted. Purdue pleaded guilty in 2007 to misleading the public about its drugs' dangers, and federal prosecutors brought additional felony charges in 2020 related to paying kickbacks to doctors and reckless sales practices. Yet the financial compensation flowing to individual victims will reach only a small fraction of those harmed.

A Maze of Deadlines

The claims process imposed a series of deadlines that proved impossible for many victims to meet. To qualify for the settlement at all, victims had to have used Purdue opioids before September 15, 2019—the day the company declared bankruptcy. The initial deadline to file claims was June 2020, though it was extended multiple times, finally closing in September 2021.

Just under 140,000 people met that final deadline. But litigation continued for years, and it wasn't until July 2025—nearly four years after the initial filing deadline—that victims had to submit evidence supporting their claims. About 63,000 did so, according to court filings from settlement trust administrator Edward Gentle.

Purdue and its attorneys moved to formally eliminate most of the 80,000 individuals who missed this evidence deadline, and a federal judge approved the expungement motion on April 21, 2026. Under certain circumstances, these excluded victims can still sue the Sackler family directly—though such individual litigation faces significant legal and financial hurdles.

The Sackler Shield

The settlement's protection of the Sackler family—Purdue's owners, who have never faced criminal charges and deny wrongdoing—has drawn sustained criticism. The family withdrew approximately $10 billion from the company in the years before Purdue's bankruptcy, a move that critics characterize as asset stripping to shield wealth from litigation.

The Supreme Court's 2024 rejection of the initial settlement specifically addressed whether bankruptcy law could properly extend liability releases to non-debtor third parties—in this case, the Sacklers, who had not personally filed for bankruptcy. The revised plan approved in November 2025 addressed this concern through different legal mechanisms, though the practical effect remains similar: victims who accept settlement payments surrender their right to sue the family.

Major law firms representing victims, including Akin and ASK LLP, endorsed the revised plan despite its tighter eligibility criteria and reduced benefits. Edward Neiger, co-managing partner of ASK LLP, cited "contractual and court-imposed confidentiality provisions" when declining to discuss the changes, but said his firm was "proud of helping facilitate the record-breaking and historic $850 million-plus settlement on behalf of the actual, human victims of the opioid crisis."

What This Means for the Crisis

The Purdue settlement's limitations illuminate broader challenges in addressing the opioid crisis through litigation. While the total value of opioid-related settlements involving drugmakers, wholesalers, and pharmacies now exceeds $50 billion, most funds flow to state and local governments rather than individual victims. Purdue's victim compensation fund, despite its limitations, remains more than eight times larger than the combined victim funds established by the other two major bankrupt opioid makers, Endo and Mallinckrodt.

For those shut out of the settlement, the legal options are narrowing. Individual lawsuits against the Sacklers remain possible but face formidable obstacles, including statutes of limitations and the family's extensive legal resources. The bankruptcy court's expungement of 80,000 claims effectively erases their standing in the consolidated litigation.

The sentencing of Purdue on three felony charges—delayed from April 21 to the following week—will mark another chapter in the company's legal reckoning, though criminal penalties against corporations rarely provide direct compensation to victims.

For Mary Jannotta and thousands like her, the settlement's failures compound the original harm. The company that marketed the drug that led to her addiction and her grandson's death will pay nothing for the losses they suffered. The documentation that might have proved their claims disappeared into the administrative void of expired medical records and elapsed deadlines.

"A punch in the gut," one victim called it—a description that captures not just the personal disappointment, but the systemic failure of a legal process that promised accountability and delivered, for most, nothing at all.